

**SOMETHING
BETTER
THAN HOPE**

Welcome & Overview

Maria T. Millan, M.D.
President & CEO
The California Institute for Regenerative Medicine
April 15-16, 2018

BRAINSTORMING NEURODEGENERATION

*Leveraging Genomics, Stem Cells, Gene
Therapy and Novel Clinical Trials
for Field-wide Advancement*

Irvine & Newport Room

CIRM
CALIFORNIA STEM CELL AGENCY

Our Mission

Accelerate Stem Cell Treatments
To Patients with
Unmet medical needs.



CIRM's role:

De-risk through early funding & advisory

Designed to Accelerate

Specialize in Translation

Stimulate Public-Private Partnerships

Connector & Convener

2004

CIRM created by Californians -Proposition 71

\$520 Million

189 grants

Funding CNS research (30% of disease areas)

2400 iPSC lines

Generated for largest bank world-wide

\$40 Million

Funding genomics initiative

Brainstorming Neurodegeneration

GOAL: To gather leaders in genomics, stem cells, clinical development, big data, patient advocacy to consider disruptive models for tackling unmet needs in neurodegeneration



BRAINSTORMING NEURODEGENERATION


*Leveraging Genomics, Stem Cells, Gene
Therapy and Novel Clinical Trials
for Field-wide Advancement*

Irvine & Newport Room

**SOMETHING
BETTER
THAN HOPE**

CIRM
CALIFORNIA STEM CELL AGENCY

What will we Brainstorm?



How can we harness the power of genomics, iPSC, clinical data to improve our understanding of ND ?



Would a consortium accelerate ND research and therapeutic development?



Consortium: An agreement, combination or group (organizations and researchers)



formed to undertake an enterprise beyond the resources of any one member



There is no pre-determined consortium & workshop participation is non-binding

Meeting Format

Invited Speakers

Panel Discussions- Strawman and Key Questions

Audience actively participate in panel discussions

Breakouts to explore potential consortium model

Consider potential path forward

Would a ND Consortium Accelerate Therapy Development?

What can we get that otherwise do not already have?

What are the components necessary to obtain that value?

How feasible is it to implement?

What incentives would facilitate key stakeholders to participate?



**BRAINSTORMING
NEURODEGENERATION**
*Leveraging Genomics, Stem Cells, Gene
Therapy and Novel Clinical Trials
for Field-wide Advancement*